"The reason given by the FDA was that the drug does not provide "a sufficient benefit in slowing disease progression to outweigh the significant risk to patients." What risk? These women are dying.
The drug buys them precious time, and the only risk they face is from an FDA saying "pull the plug."
On the same day the FDA channeled Dr. Kevorkian, its European counterpart, the European Medicines Agency, issued a statement approving Avastin for metastatic breast cancer."
No comments:
Post a Comment